StreetInsider.com News Articles

Attovia Therapeutics to Participate in Upcoming Investor Conferences

Tue, 27 Oct 2026 16:05:00 -0400

SAN CARLOS, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences:

Guggenheim 3^rd Annual Healthcare Innovation Conference
Format: Fireside chat
Date: Tuesday, November 10, 2026
Time: 3:30 PM - 3:55 PM ET

Stifel 2026 Healthcare Conference
Format: 1x1 Meetings
Date: Wednesday, November 11, 2026

2026 Jefferies Global Healthcare Conference in London
Format: 1x1 Meetings
Date: Monday, November 16 – Wednesday,

Attovia Therapeutics to Participate in Upcoming Investor Conferences

Tue, 27 Oct 2026 16:05:00 -0400

Guggenheim 3^rd Annual Healthcare Innovation Conference
Format: Fireside chat
Date: Tuesday, November 10, 2026
Time: 3:30 PM - 3:55 PM ET

Stifel 2026 Healthcare Conference
Format: 1x1 Meetings
Date: Wednesday, November 11, 2026

2026 Jefferies Global Healthcare Conference in London
Format: 1x1 Meetings
Date: Monday, November 16 – Wednesday,

Attovia to present pipeline data at two dermatology conferences

Mon, 28 Sep 2026 16:05:11 -0400

Attovia Therapeutics, Inc. (Nasdaq: ATTO) announced it will present four posters covering clinical, translational, and preclinical data at two dermatology conferences in October 2026.

Three posters will focus on ATTO-1310, an anti-IL-31 ATTOBODY-based therapeutic, and one poster will cover ATTO-2306, a bispecific antibody targeting IL-31 and IL-13.

The ATTO-1310 presentations include Phase 1a safety, pharmacokinetics, and pharmacodynamics data from healthy adults, translational data on circulating IL-31 levels across pruritic skin diseases, and interim Phase 1b results from a randomized, double-blind, placebo-controlled study in patients with atopic dermatitis or chronic pruritus.

The ATTO-2306 poster will present preclinical characterization data for the long-acting bispecific antibody

Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026

Mon, 28 Sep 2026 16:05:00 -0400

SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026.

Attovia will present four posters: three on ATTO-1310, a next generation anti-IL-31 ATTOBODY-based therapeutic, and one on ATTO-2306, a novel long-acting anti-IL-31 and IL-13 bispecific. The ATTO-1310 posters will highlight Phase 1a data in

Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026

Mon, 28 Sep 2026 16:05:00 -0400

Attovia Therapeutics to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 16:05:00 -0400

SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences:

Citi’s 2026 Biopharma Back to School Conference
Format: 1x1 meetings
Date: Thursday, September 10, 2026

Morgan Stanley 24th Annual Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, September 16, 2026
Time: 10:00 AM - 10:35 AM EST

The webcast of the Morgan Stanley fireside

Attovia Therapeutics to Participate in Upcoming Investor Conferences

Thu, 03 Sep 2026 16:05:00 -0400

Citi’s 2026 Biopharma Back to School Conference
Format: 1x1 meetings
Date: Thursday, September 10, 2026

Morgan Stanley 24th Annual Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, September 16, 2026
Time: 10:00 AM - 10:35 AM EST

The webcast of the Morgan Stanley fireside

Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Wed, 02 Sep 2026 16:05:00 -0400

ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026

Phase 2 studies of ATTO-1310 in chronic pruritus of unknown origin and high-itch AD planned for 1H 2027

Phase 1 initiation for ATTO-2306 and ATTO-1091 planned in 1H 2027

Upsized Initial Public Offering (IPO) gross proceeds of $332.4 million helps extend cash runway into 2030

SAN CARLOS, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage

Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Wed, 02 Sep 2026 16:05:00 -0400

ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026

Phase 2 studies of ATTO-1310 in chronic pruritus of unknown origin and high-itch AD planned for 1H 2027

Phase 1 initiation for ATTO-2306 and ATTO-1091 planned in 1H 2027

Upsized Initial Public Offering (IPO) gross proceeds of $332.4 million helps extend cash runway into 2030

SAN CARLOS, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage

Wall Street analysts bullish on Attovia as itch drug data fuel biotech optimism

Mon, 31 Aug 2026 09:17:25 -0400

Investing.com -- Attovia Therapeutics drew bullish coverage from three Wall Street firms this week, with analysts pointing to early clinical data for its lead chronic-itch drug candidate and the potential of its antibody platform to produce multiple therapies across large immune-mediated disease markets.

Citi initiated coverage with a Buy/High Risk rating and a $30 price target, while Morgan Stanley started the stock at Overweight with a $39 target and RBC Capital Markets initiated coverage at Outperform with a $45 target. The stock was around $20.70-$21.46 when the reports were published, implying substantial upside in all three cases.

Leerink Starts Attovia Therapeutics (ATTO) at Outperform

Mon, 31 Aug 2026 06:29:41 -0400

Leerink analyst Thomas Smith initiates coverage on Attovia Therapeutics (NASDAQ: ATTO) with a Outperform rating and a price target of $52.00.

For an analyst ratings summary and ratings history on Attovia Therapeutics click here. For more ratings news on Attovia Therapeutics click here.

Shares of Attovia Therapeutics closed at $20.70 yesterday.

LifeSci Capital Starts Attovia Therapeutics (ATTO) at Outperform

Mon, 31 Aug 2026 06:18:36 -0400

LifeSci Capital initiates coverage on Attovia Therapeutics (NASDAQ: ATTO) with a Outperform rating and a price target of $45.00.

For an analyst ratings summary and ratings history on Attovia Therapeutics click here. For more ratings news on Attovia Therapeutics click here.

Shares of Attovia Therapeutics closed at $20.70 yesterday.

Citi Starts Attovia Therapeutics (ATTO) at Buy

Mon, 31 Aug 2026 02:48:18 -0400

Citi analyst Yigal Nochomovitz initiates coverage on Attovia Therapeutics (NASDAQ: ATTO) with a Buy rating and a price target of $30.00.

For an analyst ratings summary and ratings history on Attovia Therapeutics click here. For more ratings news on Attovia Therapeutics click here.

Shares of Attovia Therapeutics closed at $20.70 yesterday.

RBC Capital Starts Attovia Therapeutics (ATTO) at Outperform

Mon, 31 Aug 2026 02:35:45 -0400

RBC Capital analyst Brian Abrahams initiates coverage on Attovia Therapeutics (NASDAQ: ATTO) with a Outperform rating and a price target of $45.00.

The analyst comments: “Validated approach and promising early data provide a clear roadmap for success of most advanced drug '1310. Nemluvio's clinical success and $1B early run-rate validate the IL-31 targeting mechanistic rationale and appetite for itch-oriented therapies, and we believe '1310, through its higher potency, ligand binding, and YTE half-life extension, has a good likelihood of ultimately demonstrating a better profile. We expect more complete ph.Ib chronic pruritus and high-itch atopic dermatitis (AD) data 4Q26/1Q27 to build upon

RBC Capital Starts Attovia Therapeutics (ATTO) at Outperform

Mon, 31 Aug 2026 02:35:45 -0400

RBC Capital analyst Brian Abrahams initiates coverage on Attovia Therapeutics (NASDAQ: ATTO) with a Outperform rating and a price target of $45.00.

Morgan Stanley Starts Attovia Therapeutics (ATTO) at Overweight

Mon, 31 Aug 2026 02:03:54 -0400

Morgan Stanley analyst Judah Frommer initiates coverage on Attovia Therapeutics (NASDAQ: ATTO) with a Overweight rating and a price target of $39.00.

The analyst comments: “We initiate coverage of Attovia Therapeutics with an Overweight rating and a $39 price target. ATTO is a clinical-stage biotech leveraging its ATTOBODY™ platform to develop differentiated, next-generation therapeutics — both mono- and multispecific in nature — for de-risked biologic targets. The company's initial focus is on targeting IL-31 for chronic itch, a strategy validated by Galderma's (covered by Thibault Boutherin) Nemluvio, which is expected to achieve >$4B in peak annual revenue across atopic dermatitis (AD)

Morgan Stanley Starts Attovia Therapeutics (ATTO) at Overweight

Mon, 31 Aug 2026 02:03:54 -0400

Morgan Stanley analyst Judah Frommer initiates coverage on Attovia Therapeutics (NASDAQ: ATTO) with a Overweight rating and a price target of $39.00.

Form 4/A Attovia Therapeutics, For: Aug 05 Filed by: WALSH COLIN

Fri, 28 Aug 2026 17:39:00 -0400

si-local-file:///var/storage/secattach/20260828/26999237.html

Form 4/A Attovia Therapeutics, For: Aug 05 Filed by: GOLDMAN SACHS & CO. LLC

Fri, 28 Aug 2026 17:38:00 -0400

si-local-file:///var/storage/secattach/20260828/26999235.html

Form 4 Attovia Therapeutics, For: Aug 05 Filed by: WALSH COLIN

Thu, 13 Aug 2026 21:53:00 -0400

si-local-file:///var/storage/secattach/20260813/26923259.html

Form 4 Attovia Therapeutics, For: Aug 05 Filed by: GOLDMAN SACHS & CO. LLC

Thu, 13 Aug 2026 21:52:00 -0400

si-local-file:///var/storage/secattach/20260813/26923258.html

Form 4 Attovia Therapeutics, For: Aug 06 Filed by: Deep Track Capital, LP

Mon, 10 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260810/26898487.html

Form 4 Attovia Therapeutics, For: Aug 06 Filed by: venBio Global Strategic Fund IV, L.P.

Mon, 10 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260810/26898020.html

Form 4 Attovia Therapeutics, For: Aug 06 Filed by: Redmile Group, LLC

Fri, 07 Aug 2026 21:47:00 -0400

si-local-file:///var/storage/secattach/20260807/26892589.html

Form 4 Attovia Therapeutics, For: Aug 06 Filed by: Sanofi

Fri, 07 Aug 2026 15:46:00 -0400

si-local-file:///var/storage/secattach/20260807/26890704.html